TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas
- 6 November 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 26 (5) , 811-825
Abstract
Background: Myeloid cells comprise up to 50% of the total tumor mass in glioblastoma (GBM) and have been implicated in promoting tumor progression and immunosuppression. Modulating the response of myeloid cells to the tumor has emerged as a promising new approach for cancer treatment. In this regard, we focus on the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), which has recently emerged as a novel immune modulator in peripheral tumors. Methods: We studied the TREM2 expression profile in various patient tumor samples and conducted single-cell transcriptomic analysis in both GBM patients and the GL261 mouse glioma model. We utilized multiple mouse glioma models and employed state-of-the-art techniques such as invivo 2-photon imaging, spectrum flow cytometry, and in vitro co-culture assays to study TREM2 function in myeloid cell-mediated phagocytosis of tumor cells, antigen presentation, and response of CD4+ T cells within the tumor hemispheres. Results: Our research revealed significantly elevated levels of TREM2 expression in brain tumors compared to other types of tumors in patients. TREM2 was predominantly localized in tumor-associated myeloid cells and was highly expressed in nearly all microglia, as well as various subtypes of macrophages. Surprisingly, in preclinical glioma models, TREM2 deficiency did not confer a beneficial effect; instead, it accelerated glioma progression. Through detailed investigations, we determined that TREM2 deficiency impaired the ability of tumor-myeloid cells to phagocytose tumor cells and led to reduced expression of MHCII. This deficiency further significantly decreased the presence of CD4+ T cells within the tumor hemispheres. Conclusions: Our study unveiled a previously unrecognized protective role of tumor-myeloid TREM2. Specifically, we found that TREM2 enhances the phagocytosis of tumor cells and promotes an immune response by facilitating MHCII-associated CD4+ T-cell responses against gliomas.Keywords
All Related Versions
Funding Information
- National Institutes of Health (R35NS132326, K99NS1177992, R01NS122174)
- Mayo Clinic Cancer Center
- Mayo Clinic Center for Biomedical Discovery
This publication has 58 references indexed in Scilit:
- TREM2 variants: new keys to decipher Alzheimer disease pathogenesisNature Reviews Neuroscience, 2016
- Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)Journal of Biological Chemistry, 2015
- TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease ModelCell, 2015
- Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Deficiency Attenuates Phagocytic Activities of Microglia and Exacerbates Ischemic Damage in Experimental StrokeThe Journal of Neuroscience, 2015
- TREM2 regulates microglial cell activation in response to demyelination in vivoActa Neuropathologica, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- CD8+ T Cell–Independent Tumor Regression Induced by Fc-OX40L and Therapeutic Vaccination in a Mouse Model of GliomaThe Journal of Immunology, 2014
- TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteriaJournal of Cell Biology, 2009
- Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2Journal of Experimental Medicine, 2005
- A Dap12-Mediated Pathway Regulates Expression of Cc Chemokine Receptor 7 and Maturation of Human Dendritic CellsJournal of Experimental Medicine, 2001